Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10466442 | 0.86 | — | — | |
| SCHEMBL9998055 | 0.86 | NOTUM (0.38) | NOTUMALDH1A1POLBSMN1; SMN2OPRM1 | |
| SCHEMBL15290736 | 0.82 | OPRM1 (0.46) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL12988080 | 0.82 | OPRM1 (0.42) | NOTUMALDH1A1POLBSMN1; SMN2OPRM1 | |
| SCHEMBL23841252 | 0.80 | MAPK1 (0.39) | NOTUMALDH1A1POLBSMN1; SMN2OPRM1 | |
| SCHEMBL20858630 | 0.80 | OPRM1 (0.49) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL23900255 | 0.80 | OPRM1 (0.49) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL1950441 | 0.80 | OPRM1 (0.49) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL23841245 | 0.78 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL20858667 | 0.78 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-9125898-B2 | Acetam derivatives for pain relief | NEUROTUNE AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| JP-2011513246-A | — | — | 2011-04-28 | — | — | JP | claimed |
| CN-102014896-A | Pharmaceutical composition comprising racetam and carnitine and process for its preparation | BIOLAB SANUS FARMACEUTICA LTDA | 2011-04-13 | — | — | CN | claimed |
| US-20110052556-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION | Biolab Sanus Farmaceutical Ltda (BR) | 2011-03-03 | — | — | US | claimed |
| EP-2262495-A2 | PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION | Biolab Sanus Farmacéutica Ltda (BR) | 2010-12-22 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009105853-A2 | PHARMACEUTICAL COMPOSITION | BIOLAB SANUS FARMACEUTICA LTDA. (BR) | 2009-09-03 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0238088-B1 | IMPROVED PROCESS FOR THE PREPARATION OF DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H)-DIONE | WARNER-LAMBERT COMPANY (US) | 1990-10-31 | — | — | EP | claimed |
| US-4663464-A | Process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| EP-0048132-B1 | THE USE OF DIHYDRO-1H-PYRROLIZINE-3,5(2H,6H)-DIONE AS A COGNITION ACTIVATOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THAT COMPOUND, AND THE PRODUCTION OF SUCH COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1984-08-15 | — | — | EP | claimed |
| EP-0095345-A2 | Tetrahydro-3,5-dioxo-1H-pyrrolizine-7a(5H)-carboxylic acids and derivatives as cognition activators | WARNER-LAMBERT COMPANY (US) | 1983-11-30 | — | — | EP | claimed |
| US-4372966-A | TREATMENT OF SENILITY, ENHANCING MEMORY, REVERSAL OF AMNESIA CAUSED BY ELECTRIC SHOCK | WARNER-LAMBERT COMPANY (US) | 1983-02-08 | — | — | US | claimed |
| EP-0048132-A2 | The use of dihydro-1H-pyrrolizine-3,5(2H,6H)-dione as a cognition activator, pharmaceutical compositions containing that compound, and the production of such compositions | WARNER-LAMBERT COMPANY (US) | 1982-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | NOTUM 3901/4885ALDH1A1 2498/4885POLB 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.